High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo

Anoumou Y Dagnra; Nicole Vidal; Akovi Mensah; Akouda Patassi; Komi Aho; Mounerou Salou; Marjorie Monleau; Mireille Prince-David; Assétina Singo; Palokinam Pitche; Eric Delaporte; Martine Peeters

doi:10.1186/1758-2652-14-30

Journal of the International AIDS Society

Table 2 Details of observed drug mutations and prediction of resistance to ARVs according to ANRS algoritm (version July 2010) and corresponding patient characteristics, CD4 counts and viral load values

From: High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo

Patient	Age	Sex	CD4 (cells/mm³)		Viral	Drug-resistance Mutations			Predicition of high level resistance to following ARVs
ID			M0	M12	load	NRTI (ex 3TC/FTC)	3TC/FTC	NNRTI
T3003	28	F	175	50	5.68	M41LM,T215NSTY,V75MV	M184V	Y181C	EFV/NVP; 3TC/FTC, D4T, AZT
T3008	32	F	70	36	5.57	K65R, (T69D)	-	K101E, Y181C, G190S	EFV/NVP; TDF
T3013	23	F	nt	507	4.75	T69N	-	K103N, Y181C	EFV/NVP
T3017	68	M	53	203	4.88	-	M184V	(A98AG), K103KN,	EFV/NVP; 3TC/FTC
T3029	39	M	21	145	6.34	-	M184V	K101E, G190A,	EFV/NVP; 3TC/FTC
T3031	36	M	100	21	4.20	M41L, T215Y, V75MV,	M184V	Y181C	EFV/NVP; 3TC/FTC, D4T, AZT
T3034	39	M	154	209	4.59	-	M184V	Y181C	EFV/NVP; 3TC/FTC
T3039	33	F	181	264	5.08	-	M184V	Y181V	ETV, EFV/NVP; 3TC/FTC
T3041	47	M	348	218	4.99	-	M184V	K101E, G190A	EFV/NVP; 3TC/FTC
T3042	35	F	16	17	5.23	T69N, Q151M	M184V	V90I, K103N, Y181C, G190A	EFV/NVP; 3TC/FTC, ABC, AZT, D4T, DDI,
T3043	37	F	276	255	4.89	-	M184V	K103N	EFV/NVP; 3TC/FTC
T3046	43	M	36	43	4.64	K70R, T215F, K219E	M184V	Y181C	EFV/NVP; 3TC/FTC, AZT, D4T
T3047	32	M	128	254	4.41	-	-	Y181C, H221HY	ETV, EFV/NVP
T3049	33	F	154	338	4.25	-	M184V	G190A	EFV/NVP; 3TC/FTC
T3061	24	F	184	410	3.43	-	M184V	V106A,	NVP; 3TC/FTC
T3067	37	F	143	264	3.32	T69S	M184V	K103N,	EFV/NVP; 3TC/FTC
T3069	40	M	143	163	3.72	T69D, K70R, K219Q	M184V	Y181C, G190A, H221Y	ETV, EFV/NVP; 3TC/FTC
T3071	40	F	80	282	3.43	T69N	M184V	Y181C	EFV/NVP; 3TC/FTC
T3073	45	M	168	58	4.08	-	-	K103N, Y181C	EFV, NVP
E5009	35	M	78	43	5.56	D67N, K65R	-	V106M, Y188C	EFV/NVP; TDF
E5011	50	M	102	148	3.32	-	M184V	Y181C	EFV/NVP; 3TC/FTC
E5013	32	F	57	112	3.20	T69N	M184V	Y181C	EFV/NVP; 3TC/FTC, DDI
E5016	33	F	173	399	4.20	-	-	Y181CY	EFV/NVP
E5017	47	M	nt	182	4.23	-	M184V	Y181V	ETV; 3TC/FTC
E5020	22	F	147	365	3.04	-	M184V	K103N	EFV/NVP; 3TC/FTC
E5024	42	M	78	197	4.41	-	M184V	(V90I), V106A,	EFV/NVP; 3TC/FTC
E5025	48	F	51	71	3.32	K65R	-	Y181C, K103N	EFV/NVP; TDF
E5027	29	F	35	84	5.08	-	-	K103KN	EFV/NVP
E5032	39	M	70	13	5.45	-	-	G190AG, K103N	EFV/NVP
E5043	46	M	27	93	3.11	-	M184V	Y181V, (A98S)	ETV; 3TC/FTC
E5044	60	F	nt	517	4.78	-	M184V	Y188L	EFV/NVP; 3TC/FTC
E5047	52	F	57	57	4.54	-	-	Y181C, K103N	EFV/NVP
E5053	35	M	99	66	5.74	(D67N, L210W)	-	Y181C, G190AG, (V90I)	EFV/NVP
E5059	41	M	118	40	4.59	(T69N )	-	Y181C	EFV/NVP
E5061	31	F	34	72	4.72	M41L	M184I,	Y181C, V90IV, A98AG, H221Y	ETV, EFV/NVP; 3TC/FTC
E5068	30	F	152	339	3.15	-	M184V	K103N, (A98G)	EFV/NVP; 3TC/FTC
C7003	34	M	98	288	4.30	-	M184V	V106A,	NVP; 3TC/FTC
C7004	38	F	185	540	4.45	-	M184V	K103N, Y181C, (V90IV)	EFV,NVP; 3TC/FTC
C7012	40	M	75	267	3.23	-	M184V	Y181C	EFV/NVP; 3TC/FTC
C7017	42	M	12	40	4.98	-	-	K103N	EFV/NVP
C7022	31	F	64	310	4.08	-	M184V	Y181C	EFV/NVP; 3TC/FTC
C7023	27	F	101	83	3.36	-	M184MV	K103N, (A98AG)	EFV/NVP; 3TC/FTC
C7024	20	F	35	84	4.00	T69D, D67G, K70R, K219Q	M184V	Y181C, G190A, H221Y	ETV, EFV/NVP; 3TC/FTC, AZT, DDI
C7028	33	M	72	12	4.36	-	-	Y181C, K103N	EFV/NVP
C7030	30	F	190	603	3.51	-	-	G190AG	EFV/NVP
C7044	55	F	nt	204	3.38	-	M184V	Y181C, H221Y	ETV, EFV/NVP; 3TC/FTC

Viral load is expressed as log₁₀ copies/ml. The abbreviations are for the following drugs: AZT - zidovudine; 3TC - lamivudine; FTC - emtricitabine; ddI - didanosine; d4T - stavudine; ABC - abacavir; TDF - tenofovir; EFV - efavirenz; NVP - nevirapine; ETV - etravirine

Back to article page

You are viewing the site in preview mode

Journal of the International AIDS Society